Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively.
4 articles
Pfizer raised its 2026 revenue forecast to $62–$64 billion after Q3 earnings beat expectations driven by Eliquis and oncology products. Strategic acquisitions and cost cuts aim to sustain growth amid
Pfizer reported better-than-expected Q2 earnings driven by Eliquis sales and announced $2.5 billion in cost cuts through 2029. The company aims to offset declining COVID revenue while expanding into t
Bristol Myers Squibb raised its full-year revenue and profit forecast after second-quarter results exceeded Wall Street estimates, driven by strong sales of Eliquis and newer medicines like Camzyos an
Bristol Myers Squibb exceeded Q1 profit expectations on strong Eliquis and cancer drug sales, boosting shares 4%. It reaffirmed its 2026 outlook and intends to leverage AI to accelerate drug discovery
ChemBrief